Fundraising FoxLongitude Capital — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
FIRE1 develops NORM, an implantable sensor placed in the inferior vena cava to directly measure fluid volume in heart failure patients, paired with a self-management platform to help patients engage with their own care.
Digital HealthHardwareMedical DevicesDublin, IE
Co-investorsAndera PartnersGimvIreland Strategic Investment FundLightstone VenturesNew Enterprise Associates (NEA)Seventure Partners+5 more
Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone.
BiotechHealthtechSouthbury, US
Kevin Russ(Chief Executive Officer)inPeter DiLaura(Chief Executive Officer and Board Director)inWaters Kellogg(Director)Lucas B. Turner(Director)Joshua Dotson(Director)Holger Koehler(Director)
Co-investorsOrbiMedWellington ManagementVersant Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.